Why the study?
Quantifying RVPAc by 2D echocardiography in severe TR has significant limitations and neglects RV volume overload or dilatation, another key indicator for right ventricular dysfunction.
Does a novel multiparametric RVPAc parameter assessed by 3D echocardiography improve prediction of 1-year mortality compared to traditional 2D RVPAc in patients undergoing T-TEER?
Does a novel multiparametric RVPAc parameter assessed by 3D echocardiography improve prediction of 1-year mortality compared to traditional 2D RVPAc in patients undergoing T-TEER?
Answers are grounded in this paper and cite their sources.
A novel 3D echocardiography-derived RVPAc parameter integrating RV function, volume stress, and pressure stress is superior to traditional 2D parameters for predicting 1-year mortality after T-TEER.
BACKGROUND: Right ventricular (RV) heart failure as assessed by RV to pulmonary artery coupling (RVPAc) is a prognostic marker in transcatheter tricuspid valve repair (T-TEER). However, quantification of RVPAc components by 2-dimensional (2D) echocardiography in patients with severe tricuspid regurgitation (TR) has significant limitations, and the traditional RVPAc parameter neglects the degree of volume overload/dilatation of the RV, which is another key clinical indicator for right ventricular dysfunction (RVD). Therefore, we aimed to assess RVD by a novel RVPAc parameter, including the 3 important drivers of RVD, for an improved prediction of 1-year mortality after T-TEER. METHODS: We analyzed 262 patients undergoing T-TEER with complete 3D RV echocardiography and 1-year follow-up. RESULTS: ]) including all 3 important drivers for RVD was developed, associating RVPA-uncoupling with a tripled risk for 1-year mortality (HR, 3.19, 1.7-6.0; P < 0.001). The novel RVPAc parameter significantly outperformed the traditional noninvasive RVPAc parameter in 1-year mortality prediction (C-index: 0.68 vs 0.57 for novel vs traditional noninvasive RVPAc; P = 0.027). CONCLUSIONS: The novel RVPAc parameter, integrating RV function, volume stress, and pressure stress is a powerful metric for RV failure and a superior predictor for survival post-T-TEER. CLINICAL TRIAL REGISTRATION: Data is based on the EveryValve Registry (ethical code number: 19-840). No further clinical Trial registration.
No takes yet. Share an insight, caveat, or question.
Doldi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: